北京美科美生物公司代理cellecta价格-博天堂备用

cas9 activity kits
cas9 expression constructs
cells
cell barcoding libraries / constructs
cdna expression
coronavirus (covid19)
crispr sgrna constructs
crispr sgrna libraries
drivermap transcriptome profiling
general dna kits
lentiviral production
sequencing of screened samples
shrna constructs
shrna libraries
tet-inducible systems and vectors

cellecta, inc. 由 clontech laboratories 的一位首席科学家于 2006 年 4 月创立。该公司是出于对更高质量、更先进的 shrna 和其他慢病毒文库的需求。我们的目标是开发高通量 (ht) 基因筛选技术及其在新治疗靶点和药物的发现和功能表征中的应用。
我们提供各种现成的产品和定制服务，可实现：
(1) 使用先进慢病毒技术的高度定制化研究，包括定制和全基因组汇集的慢病毒 shrna、crispr、crispra/i 以及任何慢病毒中任何基因组的条形码库
(2) 端到端的 rnai 和 crispr 基因筛选服务，使用汇集的慢病毒 shrna 和 crispr sgrna 文库
(3) 用于遗传筛选和其他应用的报告细胞系开发
(4) 定制稳定的 crispr 敲除、crispra/i 敲入/敲除和 shrna 敲除以及 cdna 表达等基因细胞系
(5) 使用靶向 pcr 和 ngs 发现生物标志物。凭借在高通量功能筛选方面数十年的经验，我们的科学家合作开发了一些技术，并获得了 16 项 nih sbir 资助。
cellecta 由经验丰富的管理和产品开发团队领导，该团队拥有出色的产品开发记录、外部科学合作者网络以及初创公司运营方面的先前经验。该公司位于硅谷中心的加利福尼亚州山景城，位于生物技术湾区，靠近一些最著名的研究公司和生命科学研究机构，包括基因泰克（罗氏）、斯坦福大学和加利福尼亚大学，旧金山。
尽管是一家小型私营公司，cellecta 与庞大的合作者、顾问和同事网络相连，在其专业研究领域拥有丰富的知识基础。 cellecta 与著名科学家和机构合作并发表了论文，包括罗斯威尔公园癌症研究所、弗雷德哈钦森癌症研究中心 (fhcrc)、斯克里普斯研究所 (tsri)、哈佛大学公共卫生学院、塔夫茨大学和健康研究公司。如果您有兴趣与 cellecta 合作或合作，请通过 info@cellecta.com 与我们联系
cellecta, inc. was founded in april 2006 by one of the chief scientists from clontech laboratories. the company was borne out of the need for higher quality, more advanced shrna and other lentiviral libraries. our goal was to develop advanced high-throughput (ht) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.
we offer a variety of off-the-shelf products and custom services that enable:
(1) highly customized research using advanced lentiviral technology, including custom and genome-wide pooled lentiviral shrna, crispr, crispra/i, and barcode libraries for any set of genes in any lentivector
(2) end-to-end rnai and crispr genetic screening services with pooled lentiviral shrna and crispr sgrna libraries
(3) reporter cell line development for genetic screens and other applications
(4) custom stable crispr knockout, crispra/i knock-in/knockdown, and shrna knockdown as well as cdna expression isogenic cell lines
(5) biomarker discovery using targeted pcr and ngs. with decades of experience in high-throughput functional screening, our scientists have developed some of the most advanced technologies available in collaboration with opinion leaders and with funding from 16 nih sbir grants.
cellecta is headed by an experienced management and product development team with an excellent product development track record, a network of outside scientific collaborators, and prior experience in start-up company operations. located in mountain view, ca in the heart of silicon valley, the company resides in the biotech bay area near some of the most well-known research companies and life science institutes including genentech (roche), stanford university, and the university of california, san francisco.
although a small private company, cellecta is connected to a large network of collaborators, consultants, and colleagues, with a vast knowledge base in its research areas of expertise. cellecta has partnered and published with renowned scientists and institutions, including the roswell park cancer institute, fred hutchinson cancer research center (fhcrc), the scripps research institute (tsri), harvard school of public health, tufts university, and health research, inc. if you are interested in collaborating or working with cellecta, please contact us at info@cellecta.com